cyclosporine

(redirected from Gengraf)
Also found in: Dictionary.
Related to Gengraf: Sandimmune

cyclosporine

 [si″klo-spōr´in]
a cyclic peptide from an extract of soil fungi, an inhibitor of t cell function; used as an immunosuppressant to prevent and treat rejection in organ transplant recipients and to treat severe psoriasis and as a disease-modifying antirheumatic drug.

cy·clo·spor·ine

(sī'klō-spōr'ēn),
A cyclic oligopeptide immunosuppressant produced by the fungus Tolypocladium inflatum Gams; used to inhibit organ transplant rejection.

cyclosporine

/cy·clo·spor·ine/ (-spor´ēn) a cyclic peptide from an extract of soil fungi that selectively inhibits T cell function; used as an immunosuppressant to prevent rejection in organ transplant recipients and to treat severe psoriasis and severe rheumatoid arhtritis.

cyclosporine

(sī′klə-spôr′ēn, -ĭn) also

cyclosporin

(-ĭn)
n.
An immunosuppressive drug obtained from certain soil fungi, used mainly to prevent the rejection of transplanted organs.

cyclosporine

Immunology A cyclic undecapeptide, which induces potent T-cell immunosuppression; cyclosporine mitigates GVHD, allograft rejection, ulcerative colitis, autoimmune disease, schistosomiasis; it may be of use in aplastic anemia, in combination with antilymphocyte globulin and methylprednisone for psoriasis Adverse effects Nephrotoxicity, HTN, neurotoxicity–eg, tremor, seizures, encephalopathy, headache, coma, hyperlipidemia, hyperkalemia, hypomagnesemia, HTN, anemia, anaphylaxis, nausea, paresthesias, ↑ EBV, lymphoma, pseudolymphoma, fluid retention, thromboses, hirsutism, liver toxicity Lab ↑ Creatinine, ↑ uric acid, ↑ BR, ↑ cholesterol. Cf Tacrolimus.

cy·clo·spor·ine

(sī'klō-spōr'ēn)
A cyclic oligopeptide immunosuppressant produced by the fungus Tolypocladium inflatum Gams; used to inhibit organ transplant rejection.

ciclosporin (cyclosporine) 

An immunosuppressant used in the treatment of the ocular manifestation of autoimmune diseases, uveitis, scleritis, keratoconjunctivitis sicca, ligneous conjunctivitis, and to prevent rejection of corneal grafts, etc. It is believed to exert its immunosuppressive effect by inhibiting the activation of cytotoxic T-lymphocytes. See immunosuppressants.

cy·clo·spor·ine

(sī'klō-spōr'ēn)
A cyclic oligopeptide immunosuppressant used to inhibit organ transplant rejection.

cyclosporine (sī´klōspor´ēn),

n brand name: Sandimmune;
drug class: immunosuppressant;
action: produces immunosuppression by inhibiting lymphocytes;
uses: to prevent rejection of tissues and/or organ transplants.

cyclosporine

a neutral cyclic peptide, the major metabolic product of the fungus Tolypocladium inflatum; a specific suppressor of the T lymphocyte response, important in tissue transplantation.
References in periodicals archive ?
We are very pleased that the Court's decision allows us to continue to market and sell Gengraf.
SangStat Medical Corporation, Fremont, CA, the exclusive distributor of Gengraf in the US said in a statement that it will continue to market and sell Gengraf.
3% of the dollar market share in the first two months of the fourth quarter of 2002, factory sales of Gengraf are expected to dip in the fourth quarter to $7.
Novartis said in a press release that if Abbott is ordered to withdraw Gengraf, the company will implement a Neoral Assurance Program offering confidential blood level monitoring at no charge for patients who are being switched off Gengraf to any other AB-rated cyclosporine.
The companies say that in addition, Gengraf was granted an AB rating by the FDA.
Yesterday, Novartis announced it would seek an order that Abbott withdraw Gengraf from the market.
SangStat will discuss the status of Novartis' patent lawsuit against Abbott and the potential impact on Gengraf.
a) Gengraf is a registered trademark of Abbott Laboratories, Inc.
Gengraf, a cyclosporine capsule co-promoted and distributed with Abbott Laboratories, continues to be the leading generic cyclosporine.
In order to mitigate the impact of another potential generic entrant into the cyclosporine market as well as the extent to which aggressive pricing will affect this market SangStat is reducing its estimates for Gengraf to $20M for 2001.
You can find full copies of the prescribing information for Thymoglobulin and Gengraf and copies of our latest press releases on the web at www.